Today: 11 June 2026
Wesfarmers shares slide as inflation data looms, putting ASX:WES back under A$80
6 January 2026
1 min read

Wesfarmers shares slide as inflation data looms, putting ASX:WES back under A$80

Sydney, Jan 6, 2026, 17:52 AEDT — Market closed

  • Wesfarmers fell 1.3% to A$79.78 as investors turned cautious ahead of key inflation data.
  • Australia’s benchmark closed down 0.5%, with rate bets in focus before Wednesday’s consumer price index print.
  • The next major company catalyst is Wesfarmers’ half-year results on Feb. 19.

Wesfarmers Ltd shares fell on Tuesday, last down 1.3% at A$79.78, as investors trimmed exposure to consumer-facing names ahead of an inflation report that could reset expectations for interest rates.

The move matters because inflation and rates feed quickly into household budgets in Australia, where mortgage costs can swing with policy settings. For a retail-heavy group like Wesfarmers, that backdrop can shape near-term sales momentum and margin pressure across its big chains.

Traders are also watching what the data implies for the Reserve Bank of Australia’s next step. Money markets — where investors use derivatives to bet on the path of rates — have begun repricing the odds of a move as inflation proved sticky late last year.

Broader equities ended lower, with the S&P/ASX 200 closing down 0.5% at 8,682.8 points, as losses in major banks outweighed gains in miners. BlueScope Steel jumped more than 20% after a takeover bid, giving the materials space a rare bright spot.

Investors’ immediate focus is Wednesday’s November consumer price index (CPI), a key inflation gauge, which is expected to show annual inflation slightly below the prior month, a Reuters report said. A recent pickup in inflation has prompted the central bank to rule out further rate cuts, pushing markets to price about a 33% chance of a February rate hike, the report added.

“If the market starts pricing in rate increases, the ASX is likely to see more differentiated performance across sectors rather than a broad rally,” Marc Jocum, senior product and investment strategist at Global X ETFs Australia, said in the report. Indo Premier

Wesfarmers, one of Australia’s largest listed groups, owns Bunnings, Kmart Group and Officeworks, making it a bellwether for both value-led shopping and big-ticket home improvement demand. That mix can help in a cost-of-living squeeze, but it also leaves the stock sensitive to any shift in consumer confidence tied to rate expectations.

On the chart, the A$80 level is back in focus after Tuesday’s drop below it. Traders often treat round numbers as short-term reference points because they can cluster stop-loss and buy orders, amplifying moves when prices break through.

A key risk for Wesfarmers bulls is a hotter-than-expected CPI print that lifts rate-hike odds and pressures valuation multiples across the consumer sector. The downside case is not just higher borrowing costs, but a renewed pullback in discretionary spending that shows up first in transaction volumes and promotions.

Stock Market Today

  • Jim Cramer Says Upcoming IPO Will Drive Market Action in June 2026
    June 11, 2026, 11:04 AM EDT. Jim Cramer, host of CNBC's Investing Club, highlighted an upcoming company IPO as the key market event likely to influence stock movements through the next month. Speaking candidly with Jeff Marks, Cramer emphasized the IPO's potential to set the tone for market sentiment. The duo shared insights into their decision-making processes regarding stock holdings, noting that this offering could prompt strategic shifts in portfolios. Investors and analysts alike are watching closely as this new entrant gears up to list, potentially driving volatility and trading volume across sectors.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Why MercadoLibre (MELI) stock jumped nearly 9% on Venezuela shock headlines
Previous Story

Why MercadoLibre (MELI) stock jumped nearly 9% on Venezuela shock headlines

Marks & Spencer (MKS.L) shares fall as Jan 8 Christmas trading update looms
Next Story

Marks & Spencer (MKS.L) shares fall as Jan 8 Christmas trading update looms

Go toTop